Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
Dr. Dereck Mush, MD, MBA
What they do
Panacea pairs experienced regulatory consultants with software to prepare and manage FDA submissions more quickly and predictably.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI-native FDA regulatory services
- Product type
- Service
- Stage
- Pre-seed
- Headquarters
- San Francisco, USA
- Region
- North America
- Founded
- 2026
- Total funding
- Undisclosed
Notable investors: Y Combinator.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
How Much Weight Does Real-World Evidence Actually Carry at FDA?
Dr. Dereck Mush, MD, MBA
The Agentic Clinical AI Regulatory Frontier: What ADVOCATE's $62.7M Contract Actually Unlocks
Dr. Dereck Mush, MD, MBA
Computer Vision in GI: Transforming Capsule Endoscopy into Asynchronous Care
Dr. Dereck Mush, MD, MBA